Axsome Therapeutics Inc Stock

Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors.

Axsome Therapeutics (NASDAQ: AXSM) is a mid-cap with

Shares of Axsome Therapeutics (NASDAQ: AXSM) have been on a tear, and that just accelerated today. After soaring more than 20% last month, shares of the biopharmaceutical company jumped another

Axsome Therapeutics (NASDAQ: AXSM) has been growing sales rapidly with its Auvelity antidepressant. The biopharmaceutical company focuses on developing therapies for central nervous system (CNS)

Axsome Therapeutics (NASDAQ: AXSM), a midcap biotech, went public in 2015. Since then, the stock has delivered market-beating returns thanks to significant clinical and regulatory progress, as well

Summit Therapeutics (NASDAQ: SMMT) has grown in prominence over the past three years, moving from a small-cap biotech to a large-cap valuation, driven by regulatory progress for its leading

On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics (NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter.

According to a

Herriot Tabuteau, CEO of Axsome Therapeutics (NASDAQ:AXSM), exercised and immediately sold 32,410 common shares in an open-market transaction on February 2, 2026, as disclosed in the SEC Form 4

Axsome Therapeutics (NASDAQ: AXSM) isn't one of the more famous or prominent biotech companies, but investors interested in the industry had better get to know this drugmaker. Not only has Axsome

Axsome Therapeutics (NASDAQ: AXSM) has been a red-hot stock to own over the past 12 months. During that stretch, it has soared by around 75%, dwarfing the performance of the S&P 500, which is up by

Over the past five years, Axsome Therapeutics (NASDAQ: AXSM) has been on fire. The company has crushed the market in this period on the back of solid clinical and regulatory progress. At this point